CLINICAL TRIALS PROFILE FOR MAPRACORAT
✉ Email this page to a colleague
Clinical Trials for Mapracorat
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00905450 ↗ | Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery | Completed | Bausch & Lomb Incorporated | Phase 2 | This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery. |
NCT01228513 ↗ | Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD) | Completed | Bayer | Phase 2 | The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis. |
NCT01230125 ↗ | Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery | Completed | Bausch & Lomb Incorporated | Phase 3 | The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery. |
NCT01289431 ↗ | Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis | Completed | Bausch & Lomb Incorporated | Phase 2 | The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Mapracorat
Condition Name
Clinical Trial Locations for Mapracorat
Trials by Country
Clinical Trial Progress for Mapracorat
Clinical Trial Phase
Clinical Trial Sponsors for Mapracorat
Sponsor Name